Summary

Exceptional Properties of OxyPharma's Lead Compound and Analogues
Based on the company's proprietary lead compound B-220, OxyPharma has developed new chemical entities for the treatment of Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). These molecules hold great promise for the development of new and improved treatments for two diseases where current therapies are largely unsatisfactory. OxyPharma considers these chemical entities to be promising due to factors including:

Efficacy - The molecules have proven to dramatically reduce and even eliminate the symptoms of the diseases (RA and MS) in relevant and commonly used animal models.

Safety - Rabeximod (formerly Rob 803, for the treatment of RA) has passed a preclinical safety program with a clean outcome. Results from a single and multiple dose phase I clinical trial in healthy volunteers indicate that Rabeximod is safe and well tolerated by the healthy subjects.

Administration - OxyPharma's compounds are small molecules targeted for oral administration, differentiating the company's potential therapies from almost all existing RA and MS therapies and most RA and MS drugs in late stage clinical development.

Manufacturing/Synthesis - OxyPharma's molecules are easy to manufacture (few synthesis steps), allowing low-cost manufacturing and the absence of supply restraints, a characteristic not present with most currently marketed biological agents.

Patent protection - Patent applications have been filed, and have subsequently been approved in Sweden, for the new molecules and their indications. OxyPharma expects to enjoy a strong and enduring patent protection.